Drug Search Results
More Filters [+]

Repagermanium

Alternative Names: repagermanium
Latest Update: 2024-06-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Immunostimulant

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dimerix Bioscience
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Repagermanium

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: COVID-19|Pneumonia

Phase 2: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CLARITY 2

P2

Terminated

COVID-19

2022-08-15

REMAP-CAP

P4

Active, not recruiting

COVID-19|Pneumonia

2021-01-16

Recent News Events